Why AOBiome, a U.S. microbial company, could get $30 million in round C financing.

AOBiome, a U.S. microbial company, announced a $30 million round of C financing from iCarbonX, a health big data platform.
, according to the Venture Capital Times, this round of financing will strengthen AOBiome's position as a leader in microbial drug development.
, AOBiome recently launched a phase II clinical trial using a new bacterial platform to treat hypertension.
this is the second major clinical trial of AOBiome against amino oxidizing bacteria (AOB), and last fall AOBiome conducted a Phase 2B trial of common acne.
once the experiment is successful, AOBiome's proprietary AOBs program is able to consume ammonia to produce nitrites and nitric oxide, which release key signals that regulate inflammation and vascular diaspasm.
AOBiome was founded in 2013 in Cambridge, Massachusetts, as a microbial company that sells cosmetics and sells AO-plus sprays that contain ammonia-oxidizing bacteria that convert irritating ingredients in sweat into skin-beneficial ingredients.
that AOBiome keeps people's skin healthy by breeding microbes on their skin. David Whitlock, founder of
AOBiome, says microbes are like "personal beauticians" who clean up sweat and grease from the skin, and when we use soap and shampoo, the microbes that are good for the body are destroyed.
it is understood that AOBiome is advancing a new theory of physiological health by introducing symbiotic bacteria into the natural microbiome of the human body, and that over the past decade the medical community has re-understood similar changes, such as the critical role of the gut microbiome in overall health.
modern hygiene practices have led to fewer and fewer ammonia-oxidizing bacteria that have evolved with humans," said Todd Krueger, president of AOBiome, a university in The Associated States.
reduction of ammonia oxide bacteria can lead to imbalances in the nitrogen cycle, resulting in excess ammonia and insufficient nitrogen oxides and nitrites, which in turn can lead to systemic inflammation.
iCarbonX is the ideal partner that will help us understand how to regenerate ammonia-oxidizing bacteria, inglying us with the potential to address modern diseases and improve our health systems.
" Source: Microbial Technology Applications.